ReviewJournal of diabetes science and technology2019
Glucose-Responsive Microneedle Patches for Diabetes Treatment.
Review in Journal of diabetes science and technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 95 citations in OpenAlex.
- Microfluidic-engineered glucose-responsive microparticle depot for smart insulin delivery.Drug delivery · 2026Article
- Next-generation microneedle patches for transdermal therapeutics and diagnostics.Discover nano · 2026Review
- Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics.RSC advances · 2026Review
- Material-driven glucose responsiveness in insulin delivery systems: carrier selection and performance.Frontiers in endocrinology · 2026Review
- Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.Nutrition & diabetes · 2025Review
- Organic electrochemical transceiver: An all-in-one sense-and-release device architecture for physiological modulation.Science advances · 2025Article
- Microneedle-Based Multiplexed Monitoring of Diabetes Biomarkers: Capabilities Beyond Glucose Toward Closed-Loop Theranostic Systems.ACS sensors · 2025Review
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- A Review on the Mechanisms, Applications, and Clinical Trials of Advanced Technologies in the Transdermal Drug Delivery System.Current pharmaceutical biotechnology · 2025Review
- Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.Molecular biotechnology · 2024Review
- Hypoxic environment of wounds and photosynthesis-based oxygen therapy.Burns & trauma · 2024Review
- "Smart" Matrix Microneedle Patch Made of Self-Crosslinkable and Multifunctional Polymers for Delivering Insulin On-Demand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?International journal of molecular sciences · 2023Review
- Needle Technology for Insulin Administration: A Century of Innovation.Journal of diabetes science and technology · 2023Review
- Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-Mediated Insulin Delivery.ACS nano · 2022Article
- Microneedle-based insulin transdermal delivery system: current status and translation challenges.Drug delivery and translational research · 2022Review
- Semi-Implantable Bioelectronics.Nano-micro letters · 2022Review
- Multivesicular Liposomes for Glucose-Responsive Insulin Delivery.Pharmaceutics · 2021Article
- Insulin Granule-Loaded MicroPlates for Modulating Blood Glucose Levels in Type-1 Diabetes.ACS applied materials & interfaces · 2021Article
- Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs.Acta pharmaceutica Sinica. B · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antidiabetic therapeutics, including insulin as well as glucagon-like peptide 1 (GLP-1) and its analogs, are essential for people with diabetes to regulate their blood glucose levels. Nevertheless, conventional treatments based on hypodermic administration is commonly associated with poor blood glucose control, a lack of patient compliance, and a high risk of hypoglycemia. Closed-loop drug delivery strategies, also known as self-regulated administration, which can intelligently govern the drug release kinetics in response to the fluctuation in blood glucose levels, show tremendous promise in diabetes therapy. In the meantime, the advances in the development and use of microneedle (MN)-array patches for transdermal drug delivery offer an alternative method to conventional hypodermic administration. Hence, glucose-responsive MN-array patches for the treatment of diabetes have attracted increasing attentions in recent years. This review summarizes recent advances in glucose-responsive MN-array patch systems. Their opportunities and challenges for clinical translation are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.